San Antonio A new study, co-authored by a researcher from UT Health San Antonio, found that cancer patients with COVID-19 who were treated with the anti-viral medication remdesivir had lower mortality rates than those who werent.
The observational study of 2,186 cancer patients with COVID-19 was published Wednesday in the journal Cancer Discovery.
The study used data from the COVID-19 and Cancer Consortium, of which the Mays Cancer Center, home of the UT Health San Antonio MD Anderson Cancer Center, is a part.
According to a news release from UT Health San Antonio about the study, the mortality rate of the patients in the study -- 16% -- is triple the global average.
A working draft of the study provided to KSAT before the publication, though, showed a 30-day mortality rate of 15% while the overall mortality rate was 16%.